Evaluation of the effectiveness of combination therapy of recurrent anogenital (venereal) warts: results of an observational comparative clinical study
- Authors: Rakhmatulina M.R.1, Bolshenko N.V.2, Novoselova E.Y.1, Pak V.L.3, Stovbun S.V.4, Arseenkova O.Y.5
-
Affiliations:
- State Research Center of Dermatovenereology and Cosmetology
- Central Research Institute оf Epidemiology of the Federal Service on Customers’ Rights Protection and Human Well-Being Surveillance
- Pirogov Russian National Research Medical University
- N.N. Semenov Federal Research Center for Chemical Physics Russian Academy of Sciences
- N.A. Semashko National Research Institute of Public Health
- Issue: Vol 100, No 4 (2024)
- Pages: 60-67
- Section: ORIGINAL STUDIES
- URL: https://journals.rcsi.science/0042-4609/article/view/263388
- DOI: https://doi.org/10.25208/vdv16799
- ID: 263388
Cite item
Full Text
Abstract
Background. In case of recurrent forms of the disease, combination therapy with the use of inducers interferons may be recommended.
Aims. To study the effectiveness of polysaccharides of Solanum tuberosum shoots (Panavir gel 0.002%) in the combined therapy of recurrent anogenital warts.
Methods. 60 patients: group 1 (n = 30) underwent radiowave destruction with Panavir gel 0.002% externally 2 times a day for 5 days before and 10 days after destruction, group 2 (n = 30) — radiowave destruction.
Results. Absence of itching and pain by day 5 was recorded in 27 (90.0%) patients of group 1 and 12 (40.0%) of group 2, after 10 days — in 30 (100%) and 26 (86.7%) (χ² = 4.285). Inflammatory erythema, edema and infiltration were absent after 10 days in all patients of group 1, but persisted in 7 (23,3%),12 (40.0%) and 2 (6.7%) patients of group 2 (χ² = 7.924). Epithelialization was observed for 5 days in 18 (60.0%) patients of group 1 and 10 (33.3%) patients of group 2, after 10 days — in 30 (100%) and 28 (93.3%) patients (χ² = 4.285). 90 days after therapy, relapses of the disease were recorded in 2 (6.7%) patients of group 1 and 6 (20.0%) patients of group 2 (p = 0.499), HPV elimination was observed in 11 (36.7%) and 10 (33.3%) patients (p = 0.967).
Conclusion. The effectiveness of Panavir gel 0.002% in the complex therapy of anogenital warts has been established in terms of reducing the severity of subjective and objective symptoms of the disease, as well as reducing the frequency of recurrence of rashes.
Full Text
##article.viewOnOriginalSite##About the authors
Margarita R. Rakhmatulina
State Research Center of Dermatovenereology and Cosmetology
Author for correspondence.
Email: rahmatulina@cnikvi.ru
ORCID iD: 0000-0003-3039-7769
SPIN-code: 6222-8684
Scopus Author ID: 55312504700
ResearcherId: I-5449-2014
MD, Dr. Sci. (Med.), Professor
Russian Federation, 3 bldg 6, Korolenko street, 107076 MoscowNatalia V. Bolshenko
Central Research Institute оf Epidemiology of the Federal Service on Customers’ Rights Protection and Human Well-Being Surveillance
Email: sanabol@mail.ru
ORCID iD: 0000-0001-7257-5231
SPIN-code: 1671-6476
ResearcherId: AAD-5375-2019
MD, Cand. Sci. (Med.)
Russian Federation, MoscowElena Yu. Novoselova
State Research Center of Dermatovenereology and Cosmetology
Email: novoselova@cnikvi.ru
ORCID iD: 0000-0003-1907-2592
SPIN-code: 6955-5842
Russian Federation, 3 bldg 6, Korolenko street, 107076 Moscow
Victoria L. Pak
Pirogov Russian National Research Medical University
Email: vika-pak_123@bk.ru
Russian Federation, Moscow
Sergei V. Stovbun
N.N. Semenov Federal Research Center for Chemical Physics Russian Academy of Sciences
Email: s.stovbun@chph.ras.ru
ORCID iD: 0000-0001-8820-9615
Dr. Sci. (Phys.-Math.)
Russian Federation, MoscowOlga Yu. Arseenkova
N.A. Semashko National Research Institute of Public Health
Email: omasik@gmail.com
ORCID iD: 0000-0002-1440-524X
MD, Cand. Sci. (Med.)
Russian Federation, MoscowReferences
- Gilson R, Nugent D, Werner RN, Ballesteros J, Ross J. 2019 IUSTI-Europe guideline for the management of anogenital warts. J Eur Acad Dermatol Venereol. 2020;34(8):1644–1653. doi: 10.1111/jdv.16522
- Workowski KA, Bachmann LH, Chan PA, Johnston CM, Muzny CA, Park I, et al. Sexually Transmitted Infections Treatment Guidelines,2021. MMWR Recomm Rep. 2021;70(4):1–187. doi: 10.15585/mmwr.rr7004a1
- Chesson HW, Ekwueme DU, Saraiya M, Watson M, Lowy DR, Markowitz LE. Estimates of the annual direct medical costs of the prevention and treatment of disease associated with human papillomavirus in the United States. Vaccine. 2012;30(42):6016–6019. doi: 10.1016/j.vaccine.2012.07.056
- Soper DE. In: Berek JS, ed. Novak’s Gynecology. 13th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2002. Р. 453–470.
- Wiley DJ, Douglas J, Beutner K, Cox T, Fife K, Moscicki AB, Fukumoto L. External genital warts: diagnosis, treatment, and prevention. Clin Infect Dis. 2002;35(Suppl 2):S210–S224. doi: 10.1086/342109
- Maw RD, Reitano M, Roy M. An international survey of patients with genital warts: perceptions regarding treatment and impact on lifestyle. Int J STD AIDS. 1998;9(10):571–578. doi: 10.1258/0956462981921143
- Kodner CM, Nasraty S. Management of genital warts. Am Fam Physician. 2004;70(12):2335–2342.
- Cobos C, Figueroa JA, Mirandola L, Colombo M, Summers G, Figueroa A, et al. The role of human papilloma virus (HPV) infection in non-anogenital cancer and the promise of immunotherapy: a review. Int Rev Immunol. 2014;33(5):383–401. doi: 10.3109/08830185.2014.911857
- Андосова Л.Д., Конторщикова К.Н., Шахова К.А. Патогенетические аспекты факторов местного иммунитета в различные стадии папилломавирусной инфекции. Вестник новых медицинских технологий. 2016;4:2–8. [Androsova LD, Kontorshchikova KN, Shakhova KA. Pathogenetic aspects of local immunity factors in various stages of papillomavirus infection. Vestnik novyh medicinskih tekhnologij. 2016;4:2–8. (In Russ.)] doi: 10.12737/22636
- Barton S, Wakefield V, O’Mahony C, Edwards S. Effectiveness of topical and ablative therapies in treatment of anogenital warts: a systematic review and network meta-analysis. BMJ Open. 2019;9(10):e027765. doi: 10.1136/bmjopen-2018-027765
- Аногенитальные (венерические) бородавки: клинические рекомендации,2021. [Anogenital (venereal) warts: Clinical recommendations,2021. (In Russ.)] URL: https://cr.minzdrav.gov.ru/schema/204_1
- Kalinina TS, Zlenko DV, Kiselev AV, Litvin AA, Stovbun SV. Antiviral activity of the high-molecular-weight plant polysaccharides (Panavir®). Int J Biol Macromol. 2020;161:936–938. doi: 10.1016/j.ijbiomac.2020.06.031
- Довлетханова Э.Р., Абакарова П.Р. Возможности применения противовирусных препаратов с иммуномодулирующим действием в лечении ВПЧ-ассоциированных заболеваний. Гинекология. 2014;16(5):24–26 [Dovletkhanova ER, Abakarova PR. The possibilities of using antiviral drugs with immunomodulatory effects in the treatment of HPV-associated diseases. Gynecology. 2014;16(5):24–26. (In Russ.)].
- Ибишев Х.С., Коган М.И. Лечение крупных рецидивирующих остроконечных кондилом наружных гениталий у мужчин. Урология. 2013;6:56–59 [Ibishev KS, Kogan M.I. Treatment of recurrent large external genital warts in men. Urologiia. 2013;6:56–59. (In Russ.)].
- Coleman N, Birley HD, Renton AM, Hanna NF, Ryait BK, Byrne M, et al. Immunological events in regressing genital warts. Am J Clin Pathol. 1994;102(6):768–774. doi: 10.1093/ajcp/102.6.768
- Колобухина Л.В., Носик Н.Н., Меркулова Л.Н., Брагинский Д.М., Лаврухина Л.А., Калинина Т.С., и др. Динамика индукции лейкоцитарного интерферона при однократном и повторном применении Панавира. Цитокины и воспаление. 2009;8(2):49–52 [Kolobukhina LV, Nosik NN, Merkulova LN, Braginskii DM, Lavrukhina LA, Kalinina TS, et al. Time course of leukocyte interferon induction after single and repeated application of panavir. Cytokines and Inflammation. 2009;8(2):49–52. (In Russ.)].
- Рахматулина М.Р., Большенко Н.В., Кучеров В.А., Киселев А.В., Багаева М.И. Оценка эффективности и безопасности комбинированной терапии больных с клиническими проявлениями аногенитальной папилломавирусной инфекции. Российский вестник акушера-гинеколога. 2019;19(2):84–87 [Rakhmatulina MR, Bolshenko NV, Kucherov VA, Kiselev AV, Bagaeva MI. Evaluation of the efficiency and safety of combined therapy in patients with clinical manifestationsof anogenital human papillomavirus infection. Rossiyskii Vestnik Akushera-Ginekologa = Russian Bulletin of Obstetrician-Gynecologist. 2019;19(2):84–87. (In Russ.)]. doi: 10.17116/rosakush2019190218
- Роговская С., Подзолкова Н., Оламова А. Генитальные кондиломы: терапия и профилактика. Врач. 2010;12:46–49. [Rogovskaya S, Podzolkova N, Olamova A. Genital warts: therapy and prevention. Vrach. 2010;12:46–49. (In Russ.)]
Supplementary files
